KAYO-2000
Obesity
PreclinicalActive
Key Facts
About KayoThera
Kayothera is developing a novel class of oral small molecule drugs targeting the retinoid nuclear receptor pathway, a clinically validated but previously undrugged driver of adverse metabolic and oncological outcomes. Its lead program, KAYO-1732, is a development candidate for type 2 diabetes and cardiometabolic disease, with additional programs in obesity (KAYO-2000) and male contraception (KAYO-1609). The company has garnered recognition, including winning an American Diabetes Association Innovation Challenge, and is building a strong advisory and leadership team with expertise in translation and drug development.
View full company profileTherapeutic Areas
Other Obesity Drugs
| Drug | Company | Phase |
|---|---|---|
| LET003 | Harbour BioMed | Discovery |
| LET001 | Harbour BioMed | Discovery |
| RGT-075 | Regor Therapeutics | Phase 2b |
| Anti‑Obesity Oral Drug | Premas Biotech | Phase 1 |
| Obesity Target Discovery Collaboration | Fauna Bio | Target Discovery/Preclinical |
| GLP-1 variants | Heligenics | Discovery |
| MYO Platform (Metabolic Disease) | Renbio | Pre-clinical |
| Obesity Clinical Trials | IMA Clinical Research | Not Applicable (Service) |
| MVD-1 (SANA) | Eolo Pharma | Phase 1 |
| GIP-neutralizing antibody | Helicore Biopharma | Pre-clinical |
| Antral Gastroplasty / Endoscopic Sleeve | Endo-TAGSS | Pre-clinical |
| Undisclosed siRNA Programs | Moonwalk Biosciences | Pre-clinical |